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Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model of autoimmune inflammatory
demyelination that is mediated by Th1 and Th17 cells. The transcription factor interferon regulatory factor 3 (IRF3) is
activated by pathogen recognition receptors and induces interferon-β production.
Methods: To determine the role of IRF3 in autoimmune inflammation, we immunised wild-type (WT) and irf3−/−
mice to induce EAE. Splenocytes from WT and irf3−/− mice were also activated in vitro in Th17-polarising conditions.
Results: Clinical signs of disease were significantly lower in mice lacking IRF3, with reduced Th1 and Th17 cells in
the central nervous system. Peripheral T-cell responses were also diminished, including impaired proliferation and
Th17 development in irf3−/− mice. Myelin-reactive CD4+ cells lacking IRF3 completely failed to transfer EAE in
Th17-polarised models as did WT cells transferred into irf3−/− recipients. Furthermore, IRF3 deficiency in non-CD4+
cells conferred impairment of Th17 development in antigen-activated cultures.
Conclusion: These data show that IRF3 plays a crucial role in development of Th17 responses and EAE and warrants
investigation in human multiple sclerosis.
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Experimental autoimmune encephalomyelitis (EAE) is
an animal model of multiple sclerosis (MS), an inflam-
matory demyelinating disease of the central nervous
system (CNS) [1]. Both MS and EAE are thought to be
initiated by myelin-reactive CD4+ T cells that produce
interferon-γ (IFN-γ) and interleukin-17 (IL-17) (that is,
Th1 and Th17 cells, respectively) [2-4].
Interferon regulatory factor 3 (IRF3) is a transcription
factor that, together with IRF7 and nuclear factor-κB
(NF-κB), is activated by antiviral pattern recognition re-
ceptors. IRF3 activation is part of the first line of defence
against invading viruses, and its activation results in
the production of IFN-β. This in turn, induces an* Correspondence: d.fitzgerald@qub.ac.uk; bruno.gran@nottingham.ac.uk
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unless otherwise stated.amplification loop of type I IFN, which leads to the de-
velopment of an antiviral state [5-7]. The importance of
IRF3 in the development of antiviral immunity has been
shown by using IRF3-deficient animals, which are more
susceptible to viral infection. In addition, IRF3/IRF7
double-knockouts do not produce IFN-γ in response
to viruses and are severely impaired in their antiviral
responses [8].
Toll-like receptor (TLR) signalling can be divided
broadly into MyD88-dependent and MyD88-independent
pathways. IRF3 is activated through the MyD88-
independent pathway. TLRs 3 and 4 recruit the
adaptor molecule Toll-IL-1 resistance domain–containing
adaptor-inducing IFN-β (TRIF) (TLR4 also uses TRIF-
related adaptor molecule) [5]. TRIF then interacts with
TANK-binding kinase 1 (TBK1), RIP1 and tumour necro-
sis factor (TNF) receptor–associated factor [9]. TBK1,
along with inhibitor of NF-κB kinase ε, phosphorylates
IRF3, which facilitates its translocation into the nucleusral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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promoters, the IFN-β promoter in particular.
The role of IRFs in EAE and MS has received limited
attention. Tada and colleagues showed that IRF1 plays a
proinflammatory role in EAE [11], and, recently, Huber
et al. showed that IRF4 promotes CD8+ T-cell–mediated
EAE [12]. Tzima et al. found that mice with heme oxy-
genase 1 deficiency in myeloid cells exhibited enhanced
EAE severity which was associated with a lack of IRF3
activation [13]. To our knowledge, our present study is
the first in which the impact of IRF3 deficiency in EAE
has been investigated.
On the basis of previous studies showing the protect-
ive effect of type I IFN signalling in EAE [14-17], we
expected irf3−/− mice to develop more severe EAE.
Compellingly, irf3−/− mice in fact developed significantly
less severe EAE with less CNS infiltration and dimin-
ished T-cell responses, including proliferation and Th17
development. Furthermore, myelin-reactive CD4+ T cells
lacking IRF3 completely failed to transfer EAE in an
IL-23-driven, Th17-biased model, as did WT cells trans-
ferred into irf3−/− recipients. IRF3 deficiency in non-
CD4+ cells, but not in CD4+ cells, conferred impairment
of Th17 development in antigen-activated cultures. These
data implicate IRF3 in the pathogenesis of autoimmune
inflammation and Th17 responses.
Methods
Experimental autoimmune encephalomyelitis induction
EAE was actively induced in 8- to 12-week-old female
C57BL/6 mice (The Jackson Laboratory, Bar Harbor,
ME, USA) and irf3−/− mice by subcutaneous injection of
150 μg of myelin oligodendrocyte glycoprotein (MOG35–55)
in complete Freund’s adjuvant (CFA) medium containing
5 mg/ml Mycobacterium tuberculosis. Bordetella pertussis
toxin (PT) was administered intraperitoneally (200 ng/
mouse) on day 0 and day 2. To adoptively transfer EAE,
C57BL/6 or irf3−/− mice were immunised subcutaneously
with 200 μg of MOG35–55 in CFA medium at four sites on
the back. Mice were sacrificed after 9 to 12 days, and their
lymph nodes and spleens were retrieved. Cells were cul-
tured (spleens and lymph nodes combined) at a density of
8 × 106 cells/ml in RPMI 1640 medium with 10% foetal
calf serum (FCS) and penicillin-streptomycin, L-glutamine,
2-mercaptoethanol, 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid and sodium pyruvate in 150 ×
25–mm Petri dishes. Cells were cultured for 3 days
with IL-23 (20 ng/ml) at 37°C recovered, and CD4+
cells were purified with anti-CD4-conjugated magnetic
beads (Miltenyi Biotec, Surrey, UK). Cells were resus-
pended in phosphate-buffered saline (PBS), and 5 × 106
cells were injected via the tail vein into recipient mice.
PT was injected intraperitoneally (200 ng/injection) on
day 0 and day 2. Mice were scored daily for clinicalsigns of disease according to the following scale: partial
limp tail, 0.5; full limp tail, 1; limp tail and waddling
gait, 1.5; paralysis of one hindlimb, 2; paralysis of one
hindlimb and partial paralysis of other hindlimb, 2.5;
paralysis of both hindlimbs, 3; ascending paralysis, 3.5;
paralysis of trunk, 4; moribund, 4.5; death, 5. Cumula-
tive scores were calculated by adding together all daily
scores for an individual mouse to yield a single cumu-
lative score value for each mouse. All studies were per-
formed with the approval of the institutional animal
care and use committee of Thomas Jefferson University
(Philadelphia, PA, USA) or in compliance with the UK
Home Office and approved by the Queen’s University
Ethical Review Committee.
Isolation of central nervous system cells
Spinal cords were removed from the mice after transcar-
dial perfusion with PBS. Mononuclear cells were isolated
by Percoll gradient centrifugation. Pooled cells were cul-
tured for 4 hours in RPMI 1640 medium containing 10%
FCS and stimulated with phorbol 12-myristate 13-acetate
(50 ng/ml), ionomycin (500 ng/ml) and GolgiPlug protein
transport inhibitor (1 μg/106 cells; BD Biosciences, San
Jose, CA, USA).
T-cell activation in vitro
Spleens were harvested from wild-type (WT) and irf3−/−
mice, and single-cell suspensions were prepared fol-
lowing erythrocyte lysis. Cells were cultured at a dens-
ity of 2 × 106 cells/ml in X-VIVO 15 medium (Lonza,
Walkersville, MD, USA) or Iscove’s modified Dulbecco’s
medium and activated with anti-CD3/anti-CD28 anti-
bodies or with MOG35–55 (25 μg/ml) in the presence or
absence of the following cytokines and antibodies for
3 days as indicated: transforming growth factor-β (TGF-β)
(2 ng/ml), IL-6 (20 ng/ml), TNF-α (10 ng/ml), IL-1β
(10 ng/ml), IL-23 (10 ng/ml), IL-12 (10 ng/ml) and anti-
IFN-γ (10 μg/ml) for 3 days. CD4+ and CD4− cells were
purified prior to culture by immunomagnetic separation
(Miltenyi Biotec) and cultured in various combinations
as indicated.
Flow cytometry
Flow cytometric analysis of splenocytes and mono-
nuclear cells from the CNS was performed as previously
described [18]. Briefly, cells were washed and blocked
with anti-CD16/anti-CD32 antibodies. Blocked cells were
stained for 20 minutes in the dark with fluorescence-
labelled antibodies to a range of cell surface markers (BD
Pharmingen, San Diego, CA, USA). For intracellular
staining, cells were washed, fixed and permeabilised
using FIX & PERM cell permeabilisation reagents (Caltag
Laboratories, Burlingame, CA, USA). Cells were intracel-
lularly stained for IL-17 and IFN-γ. Data were acquired on
Table 1 Incidence of actively induced experimental
autoimmune encephalomyelitis in wild-type and
irf3−/− micea
Experiment Wild type IRF3−/−
1 7/7 (100%) 5/6 (83%)
2 4/6 (67%) 7/7 (100%)
3 5/5 (100%) 2/8 (25%)
4 6/6 (100%) 1/6 (17%)
5 4/5 (80%) 2/5 (40%)
Total 26/29 (90%) 17/32 (53%)
aWild-type and interferon regulatory factor 3–knockout (irf3−/−) mice were
immunised with myelin oligodendrocyte glycoprotein (MOG35–55) in Complete
Freund’s adjuvant, and Bordetella pertussis toxin was administered on day 0 and
day 2. Mice were scored daily for clinical signs of experimental autoimmune
encephalomyelitis. Data represent disease incidence in each group in five
independent experiments.
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analysed using FlowJo software (TreeStar, Ashland, OR,
USA).
Cytokine analysis
Splenocytes from EAE experiments were cultured for
72 hours ex vivo with MOG35–55 (25 μg/ml) or anti-
CD3/anti-CD28 (1 μg/ml) at a density of 2 × 106 cells/ml
in RPMI 1640 medium containing 10% FCS, penicillin-
streptomycin, L-glutamine and nonessential amino acids.
Supernatant cytokine concentrations from all splenocyte
cultures were measured by enzyme-linked immunosorb-
ent assay (IL-17; R&D Systems, Minneapolis, MN, USA).
Proliferation assay
Splenocytes were cultured for 48 hours with MOG35–55
(25 μg/ml) or anti-CD3/anti-CD28 (1 μg/ml) at a density
of 2 × 106 cells/ml in X-VIVO 15 medium. T cell prolif-
eration was measured by [3H]thymidine incorporation as
previously described [19].
Statistical analysis
Clinical scores were tested for statistical significance by
comparing areas under the curve for each animal and
comparing groups with a nonparametric Mann-Whitney
U test. Cytokine production and proliferative responses
of WT and irf3−/− mice were compared using an unpaired
two-tailed Student’s t test.
Results and discussion
Deficiency of interferon regulatory factor 3 inhibits
experimental autoimmune encephalomyelitis
To investigate the role of IRF3 in CNS autoimmune
inflammation, we induced EAE in WT and irf3−/− mice
with MOG35–55 in CFA medium. Surprisingly, we consist-
ently observed significantly less severe disease in irf3−/−
mice (Figure 1A). Disease incidence was also significantly
lower in irf3−/− groups (Table 1), as were maximal andFigure 1 IRF3-deficient mice develop less severe experimental autoim
factor 3–knockout (IRF3ko, irf3−/−) and wild-type (WT) mice were immunise
Freund’s adjuvant, and Bordetella pertussis toxin was administered on day 0
autoimmune encephalomyelitis. Data represent average ± SEM of five pooled
scores reached in irf3−/− and WT mice in five independent experiments overcumulative clinical scores in five independent experiments
(Figures 1B and 1C). These data indicate that IRF3
contributes to the pathogenesis of EAE.
To investigate potential roles of IRF3 in EAE pathogen-
esis, we examined CNS inflammatory infiltrates. We ob-
served fewer total cells in pooled spinal cords of irf3−/−
mice with EAE than in their WTcounterparts (Figure 2A).
We analysed infiltrates by flow cytometry and observed
slightly lower proportions of both CD4+ and CD8+ cells in
the CNS of irf3−/− mice (Figure 2B). Given the central role
for CD4+ T cells in EAE pathogenesis, we examined the
helper T cell subsets in the CNS infiltrate. We observed a
lower proportion of both Th1 (CD4+IFN-γ+) and Th17
(CD4+IL-17+) cells, as well as CD4+ cells, producing both
IFN-γ and IL-17 in irf3−/− mice (Figure 2C).
We next examined the peripheral immune response in
spleens of immunised WT and irf3−/− mice. We observed
significantly lower proliferative responses to polyclonal
stimulation in splenocytes of irf3−/− mice (Figure 3A).
There was also a trend towards reduced antigen-specific
proliferation to MOG35–55 (Figure 3A). We next examinedmune encephalomyelitis than wild-type mice. Interferon regulatory
d with myelin oligodendrocyte glycoprotein (MOG35–55) in complete
and day 2. (A) Mice were scored daily for clinical signs of experimental
experiments (see Table 1). Mean maximal (B) and cumulative (C) clinical
the full duration of disease are shown.
Figure 2 IRF3-deficient mice have less central nervous system
infiltration in experimental autoimmune encephalomyelitis.
Spinal cords were dissected from perfused interferon regulatory factor
3–knockout (irf3−/−) and wild-type (WT) mice, and mononuclear cells
were isolated by Percoll gradient centrifugation. (A) The absolute
numbers of central nervous system mononuclear cells in irf3−/− and
WT mice were determined. (B) and (C) Cells were cultured for 4 hours
with phorbol 12-myristate 13-acetate and ionomycin in the presence
of GolgiPlug protein transport inhibitor. Cells were stained for CD4 and
CD8 (B). The percentages of positive gated live cells are displayed. Cells
were intracellularly stained for interleukin-17 (IL-17) and interferon-γ
(IFN-γ) (C). The percentages of positive gated CD4+ live cells are dis-
played. Cells from one representative experiment (harvested on day 22
after immunisation) of two is shown.
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CD3/anti-CD28 or with MOG35–55. Expression of IL-17
was significantly lower in splenocytes from irf3−/− mice that
were polyclonally activated or activated with MOG35–55
(Figure 3B), suggesting that IRF3 may play a role in IL-17
production by T cells.
IRF3 deficiency impairs Th17 differentiation
As both Th1 and Th17 cells were found at lower frequen-
cies in the CNS of irf3−/− mice with EAE than in the WTmice (Figure 2C), we investigated the impact of IRF3 defi-
ciency on Th1 and Th17 differentiation in vitro. Consist-
ently, IRF3 deficiency resulted in increased proportions of
Th1 cells (CD4+IFN-γ+) in all conditions tested (Figure 4A).
Conversely, proportions of Th17 cells (CD4+IL-17+) were
lower in irf3−/− cultures than in WT cultures in Th17-
polarised cultures (Figure 4A), the only condition in which
robust IL-17 expression was observed (TGF β + IL-6 + IL-
1β + anti-IFN-γ). These findings demonstrate that IRF3 me-
diates helper T cell polarisation with opposing supportive
and inhibitory effects on Th17 and Th1 differentiation,
respectively. Thus, although proportions of both Th1 and
Th17 subsets were reduced in the CNS of mice with EAE
(Figure 2C), it is likely that reduced Th17 development was
a limiting factor in the development of EAE in irf3−/− mice.
Of note, certain Th17 polarisation experiments included
neutralising anti-IFN-γ antibody to ensure that differences
were not due to the observed increase in IFN-γ production
in the absence of IRF3 (Figure 4A). We also examined
additional Th17-polarising cytokine cocktails that support
de novo differentiating (TGF-β + IL-6 + IL-1β +TNF-α) and
differentiated (IL-23) Th17 cells, and we consistently
observed less IL-17 production in IRF3-deficient cultures
(Figure 4B). These data provide strong evidence that IRF3
is involved in Th17 cell development and function.
IRF3-deficient T cells fail to transfer experimental
autoimmune encephalomyelitis
To investigate the role of IRF3 specifically in Th17-
cell pathogenicity, we used a Th17-biased model of
adoptively transferred EAE. WT and irf3−/− donors
were immunised with MOG35–55 in CFA medium, and
peripheral lymphoid organs were harvested and reacti-
vated with antigen in vitro in the presence of exogenous
IL-23. CD4+ cells were purified and transferred intraven-
ously to naive recipient WT mice. Strikingly, irf3−/− CD4+
cells failed to induce EAE in any recipient animal in three
independent experiments (Figure 4C and Table 2). These
findings demonstrate a key role for IRF3 in the pathogen-
icity of Th17 cells in EAE. Interestingly, as purified CD4+
T cells (WT or irf3−/−) were transferred to WT recipients,
the findings from this study could have pointed towards a
central role for direct, T-cell intrinsic IRF3 activity in
influencing Th17 differentiation and pathogenicity. How-
ever, transfer of WT CD4+ cells to irf3−/− recipients also
failed to induce clinical EAE in any animals in two replicate
experiments (Figure 4C and Table 2), suggesting that T-cell
extrinsic mechanisms are also involved in the lack of disease
observed in IRF3-deficient recipients of WT CD4+ Tcells.
Thus, we sought to address whether CD4+ T cell in-
trinsic or extrinsic IRF3 activity influenced Th17 differ-
entiation. Splenocytes and lymph nodes from WT and
irf3−/− mice were harvested 7 days after immunisation
with MOG35–55. CD4
+ and CD4− fractions were prepared
Figure 3 Diminished T-cell responsiveness in irf3−/− mice with experimental autoimmune encephalomyelitis. Spleen cells from interferon
regulatory factor 3–knockout (irf3−/−) and wild-type (WT) mice (n = 5 or 6 mice/group) harvested 18 to 22 days after immunisation were cultured
in triplicate in the presence of MOG35–55 or anti-CD3/anti-CD28. (A) After 48 hours of culture, proliferative responses to myelin oligodendrocyte
glycoprotein (MOG35–55) or anti-CD3/anti-CD28 were determined. Proliferative responses are shown as mean counts per minute (cpm) ± SEM.
(B) After 72 hours of culture, interleukin-17 (IL-17) production in response to MOG35–55 or anti-CD3/anti-CD28 was determined in supernatants
by enzyme-linked immunosorbent assay. One representative experiment of two is shown.
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binations in which IRF3 deficiency was restricted to CD4+
cells, CD4− cells, all cells or none. Cultures were reacti-
vated with MOG35–55 in Th17-polarising conditions.
Strikingly, IL-17 production was impaired when all cells
were deficient in IRF3 and when CD4− cells were deficient
in IRF3, but not when only CD4+ cells lacked IRF3
(Figure 4D). These data show that, during antigen activa-
tion of CD4+ T cells, IRF3 activity in non-CD4+ T cells is
required for maximal Th17 responses.
The findings of these studies are surprising, consider-
ing that type I IFN has been found to be protective in
EAE in studies of IFN-α/β receptor–deficient mice and
IFN-β-deficient mice [15-17]. Furthermore, we have pre-
viously shown that activation of TLR3 with polyinosinic-
polycytidylic acid, which signals via IRF3, suppresses
relapsing–remitting EAE in SJL mice [20]. This was also
shown in chronic EAE by Tzima et al. [13]. However,
these paradoxical findings may be explained in part by
findings reported by Axtell et al. [21], who showed that,
though IFN-β suppressed EAE in a Th1 model, the
severity of EAE in an IL-23-driven Th17 model was in
fact exacerbated by IFN-β. As signalling through IRF3
results in IFN-β production, IRF3 deficiency may abro-
gate such an exacerbating effect of IFN-β, particularly in
IL-23-driven autoreactive T cells. In addition, Al-Salleeh
and Petro have shown that the IL-23p19 promoter con-
tains a binding site for IRF3 [22], and Smith et al. have
reported increased IRF3 binding to the IL-23p19 pro-
moter in monocytes taken from patients with systemic
lupus erythematosus [23]. In a recent study of theinhibition of IL-23 by morphine, Ma et al. reported in-
hibition of IRF3 phosphorylation and suggested that this
may underlie the observed inhibition of IL-23 [24]. Of
note, however, we observed impaired IL-17 responses in
cultures supplemented with IL-23; thus, a lack of IRF3-
driven IL-23 does not completely explain the decreased
Th17 responses in our studies. In addition to recent dis-
coveries pertaining to IL-23, IRF3 has been shown to
inhibit Th1 responses by binding to the Il12b promoter
and negatively regulating Il12b expression [25]. Indeed,
irf3−/− dendritic cells infected with vesicular stomatitis
virus induced enhanced Th1 responses in naive syngeneic
recipients associated with increased Ifng expression [25].
Similarly, in our present study, we observed enhanced
Th1 differentiation during in vitro T cell activation in
non-polarised and Th1- and Th17-polarising conditions.
It is tempting to speculate that such enhanced Th1
development in the absence of IRF3 inhibited Th17
development in our cultures. However, it is noteworthy
that neutralisation of IFN-γ in our cultures did not
restore Th17 polarisation in irf3−/− cultures to levels of
WTcells.Conclusion
Collectively, the data reported here lend support to a
role for IRF3 in driving the IL-23/Th17 axis and the
pathogenesis of CNS autoimmune inflammation. These
data indicate that IRF3 plays a critical role in the devel-
opment of Th17 responses and MOG35–55-induced EAE
and thus warrants investigation in human MS.
Table 2 Incidence of adoptively transferred experimental
autoimmune encephalomyelitis with CD4+ cells from irf3−/−
and wild-type donorsa
Experiment WT to WT irf3−/− to WT WT to irf3−/−
1 6/6 (100%) 0/4 (0%) 0/6 (0%)
2 7/7 (100%) 0/4 (0%) –
3 4/5 (80%) 0/5 (0%) –
4 3/3 (100%) – 0/5 (0%)
Total 20/21 (95%) 0/13 (0%) 0/11 (0%)
aWild-type (WT) and interferon regulatory factor 3–knockout (irf3−/−) mice were
immunised with myelin oligodendrocyte glycoprotein (MOG35–55) in complete
Freund’s adjuvant medium. After 10 days, cells from spleens and lymph nodes were
reactivated with MOG35–55 in the presence of interleukin-23 for 3 days. Cells were
transferred intravenously into naive WT or irf3−/− recipient mice that received
Bordetella pertussis toxin on day 0 and day 2 after cell transfer. Mice were scored daily
for clinical signs of disease. Data represent disease incidence in each group in two to
four independent experiments, and headings describe donor-to-recipient transfers.
Figure 4 Interferon regulatory factor 3 supports Th17 cell differentiation and pathogenicity. (A) Splenocytes cells from naive interferon
regulatory factor–knockout (KO, irf3−/−) and wild-type (WT) mice were activated with anti-CD3/anti-CD28 (1 μg/ml) in non-polarised (no exogenous
cytokines), Th1-polarising (interleukin-12 (IL-12)) or Th17-polarising (transforming growth factor β (TGF-β), IL-6, IL-1β and antibody against interferon γ
(anti-IFN-γ)) conditions for 3 days. Helper T (Th) cell polarisation was analysed by flow cytometry following restimulation with phorbol 12-myristate
13-acetate/ionomycin/GolgiPlug protein transport inhibitor for the final 4 hours of culture. The percentages of positive gated CD4+ live cells are displayed.
(B) Splenocytes were activated in other Th17-polarising conditions as indicated for 3 days, and IL-17 production was measured by enzyme-linked
immunosorbent assay (ELISA). (C) WT and irf3−/− mice were immunised with myelin oligodendrocyte glycoprotein (MOG35–55) in complete Freund’s
adjuvant. After 10 days, cells from the spleens and lymph nodes were reactivated with MOG35–55 (25 μg/ml) in the presence of IL-23 (20 ng/ml) for 3 days.
Cells were transferred into naive WT or irf3−/− recipient mice. Mice were scored daily for clinical signs of disease (see Table 2). (D) Spleens and lymph nodes
were harvested from WT and irf3−/− mice that had been immunised with MOG35–55 for 7 days. CD4
+ and CD4− populations were immunomagnetically
purified and cultured in combinations as indicated. Cultures were reactivated with MOG35–55 (25 μg/ml) in the presence of IL-23 (20 ng/ml), and IL-17 was
measured by ELISA (n= 4). Data from one experiment representative of two or three replicate experiments are shown.
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